Biora Therapeutics(BIOR) - 2024 Q1 - Quarterly Results

Biora Therapeutics Provides Corporate Update and Reports Dosing of all patients in clinical trial of BT-600 has been successfully completed, with results anticipated in late Q2 2024 Partnering process for the BioJet oral delivery platform is progressing well SAN DIEGO, May 15, 2024 – Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today provided a corporate update and reported financial results for the first quarter ended March 31, 2024. "We continue to ...